Clinical Trial

A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 19, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial was designed to evaluate the safety and efficacy of Y90-SIRT combined with nivolumab, ipilimumab, and lenvatinib in patients with unresectable HCC. In addition to assessing short-term efficacy endpoints, such as ORR and PFS, this trial places particular emphasis on the OS benefit for patients. This study is therefore both novel and innovative.
Trial Details
NCT Number NCT07482059
Lead Sponsor West China Hospital
Conditions Unresectable Hepatocellular Carcinoma
Enrollment 33 participants
Start Date 2026-02
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-19